Mahesh Anantha Narayanan, MD
Interventional Cardiology · Little Rock, ARNPI 1154763449
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $15,973 of the $25,855 with a category attached, or 61.8%. Medtronic accounts for 65.1% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2023 at $14,577 and has fallen 67.2% since, to $4,786 in 2025.
Across 277 payments — averaging $93.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$17K
- Shockwave Medical, Inc$3K
- Abbott$2K
- Endologix LLC$949
- Boston Scientific$747
- Abiomed$381
- plus $2K from 24 others
What the payments were for
- Travel & lodging$15,97362%
- Food & beverage$9,88238%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 103 | $16,836 |
| Shockwave Medical, Inc | 45 | $3,012 |
| Abbott | 23 | $2,234 |
| Endologix LLC | 4 | $949 |
| Boston Scientific | 28 | $747 |
| Abiomed | 5 | $381 |
| Silk Road Medical, Inc. | 4 | $260 |
| Avinger Inc. | 11 | $211 |
| Livanova USA, Inc. | 4 | $186 |
| Cvrx, Inc. | 3 | $120 |
| Teleflex LLC | 1 | $98 |
| Novartis | 6 | $89 |
| AstraZeneca | 6 | $89 |
| Johnson & Johnson | 3 | $82 |
| Merck | 4 | $73 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $67 |
| Pfizer | 4 | $58 |
| Asahi Intecc USA, Inc. | 2 | $52 |
| Boehringer Ingelheim | 3 | $46 |
| Amgen | 2 | $39 |
| Edwards Lifesciences | 2 | $36 |
| Lexicon Pharmaceuticals, Inc. | 2 | $34 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $30 |
| Canon Medical Systems USA, Inc. | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $23 |
| Bard Peripheral Vascular, Inc. | 1 | $20 |
| Angiodynamics, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Bayer | 1 | $14 |
| Terumo Medical Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESOLUTE ONYX$11,454
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,874
- Micra$1,668
- AVEIR$833
- AFX2 Bifurcated Endograft System$727
- ASSURITY$574
- AMPLIA MRI QUAD CRT-D SURESCAN$357
- Impella$250
- Alto Abdominal Stent Graft System$182
- COROFLOW$146
- JETi Peripheral Catheter$142
- Ultreon$128
- AZURE XT DR MRI SURESCAN$100
How this compares
$25,855 in reported general payments places this provider in the 85th percentile of 89 interventional cardiology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 309 | $216,570 |
| EntrestoSacubitril/Valsartan | 127 | $107,550 |
| XareltoRivaroxaban | 130 | $87,873 |
| Repatha SureclickEvolocumab | 91 | $59,393 |
| FarxigaDapagliflozin Propanediol | 89 | $58,998 |
| JardianceEmpagliflozin | 42 | $40,459 |
| BrilintaTicagrelor | 32 | $17,192 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,652 |
| VerquvoVericiguat | 11 | $7,284 |
| Atorvastatin Calcium | 476 | $3,449 |
| ClopidogrelClopidogrel Bisulfate | 435 | $3,180 |
| Prasugrel Hcl | 84 | $2,754 |
| Metoprolol Succinate | 277 | $2,550 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 99 | $2,391 |
| Amiodarone Hcl | 104 | $2,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $58 | $216,570309 claims |
| NovartisEntresto | $89 | $107,550127 claims |
| Johnson & JohnsonXarelto | $82 | $87,873130 claims |
| AstraZenecaFarxiga, Brilinta | $89 | $76,190121 claims |
| Boehringer IngelheimJardiance | $46 | $40,45942 claims |
| MerckVerquvo | $73 | $7,28411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 89 interventional cardiology providers in Arkansas.
Other interventional cardiology in Little Rock
- Gaurav DharLittle Rock$206K
- Ernesto Ruiz-RodriguezLittle Rock$153K
- Vasili LendelLittle Rock$86K
- Thomas WattsLittle Rock$68K
- Vijay RajaLittle Rock$46K
- Stephen BroughtonLittle Rock$34K
- Aravind RaoLittle Rock$17K
- Patrick TobbiaLittle Rock$14K
- Subhi AlarefLittle Rock$13K
- Hamza RayesLittle Rock$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.